Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

被引：1
|
作者：
Lopez, Carlos A. [1 ]
Wu, Vernon [2 ]
Rhodes, Joanna M. [3 ,4 ,5 ]
Rai, Kanti R. [5 ]
Barrientos, Jacqueline [5 ]
机构：
[1] Monter Canc Ctr, Lake Success, NY USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Med, Div Hematol, New Hyde Pk, NY USA
[3] Monter Canc Ctr, Northwell Hlth Canc Inst, CLL Res & Treatment Program, Lake Success, NY USA
[4] Donald & Barbara Zucker Sch Med, Lake Success, NY USA
[5] Donald & Barbara Zucker Sch Med Hofstra Northwell, Monter Canc Ctr, Northwell Hlth Canc Inst, Lake Success, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-153947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4698
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [1] Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial
    Jain, Nitin
    Basu, Sreyashi
    Thompson, Philip A.
    Ohanian, Maro
    Ferrajoli, Alessandra
    Pemmaraju, Naveen
    Cortes, Jorge E.
    Estrov, Zeev
    Burger, Jan A.
    Neelapu, Sattva S.
    Lopez, Wanda
    Thakral, Beenu
    Bueso-Ramos, Carlos E.
    Blando, Jorge
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    Allison, James
    Keating, Michael
    Sharma, Padmanee
    Wierda, William G.
    BLOOD, 2016, 128 (22)
  • [2] A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation
    Jain, Nitin
    Ferrajoli, Alessandra
    Basu, Sreyashi
    Thompson, Philip A.
    Burger, Jan A.
    Kadia, Tapan M.
    Estrov, Zeev E.
    Pemmaraju, Naveen
    Lopez, Wanda
    Thakral, Beenu
    Khoury, Joseph David
    Bueso-Ramos, Carlos E.
    Blando, Jorge
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    Allison, James P.
    Keating, Michael J.
    Sharma, Padmanee
    Wierda, William G.
    BLOOD, 2018, 132
  • [3] Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies
    Pflug, Natali
    Chakupurakal, Geothy
    Fink, Anna-Maria
    Robrecht, Sandra
    Herling, Marco
    Cramer, Paula
    Holtick, Udo
    Theurich, Sebastian
    Schetelig, Johannes
    Fischer, Kirsten
    Ritgen, Matthias
    Scheid, Christof
    Eichhorst, Barbara
    Dreger, Peter
    Hallek, Michael
    von Bergwelt-Baildon, Michael
    HEMASPHERE, 2021, 5 (12):
  • [4] Efficacy of Ibrutinib Monotherapy in PreClinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue
    Chen, Shih-Shih
    Barrientos, Jacqueline
    Yan, Xiao-Jie
    Wirtz, Uwe
    Szafer-Glusman, Edith
    Rai, Kanti R.
    Chiorazzi, Nicholas
    BLOOD, 2021, 138 : 3708 - +
  • [5] A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
    Jain, Nitin
    Senapati, Jayastu
    Thakral, Beenu
    Ferrajoli, Alessandra
    Thompson, Philip
    Burger, Jan
    Basu, Sreyashi
    Kadia, Tapan
    Daver, Naval
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Parry, Erin
    Wu, Catherine J.
    Khoury, Joseph
    Bueso-Ramos, Carlos
    Garg, Naveen
    Wang, Xuemei
    Lopez, Wanda
    Ayala, Ana
    O'Brien, Susan
    Kantarjian, Hagop
    Keating, Michael
    Allison, James
    Sharma, Padmane
    Wierda, William
    BLOOD ADVANCES, 2023, 7 (10) : 1958 - 1966
  • [6] The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
    Reiff, Sean D.
    Mantel, Rose
    Smith, Lisa L.
    Greene, J. T.
    Muhowski, Elizabeth M.
    Fabian, Catherine A.
    Goettl, Virginia M.
    Tran, Minh
    Harrington, Bonnie K.
    Rogers, Kerry A.
    Awan, Farrukh T.
    Maddocks, Kami
    Andritsos, Leslie
    Lehman, Amy M.
    Sampath, Deepa
    Lapalombella, Rosa
    Eathiraj, Sudharshan
    Abbadessa, Giovanni
    Schwart, Brian
    Johnson, Amy J.
    Byrd, John C.
    Woyach, Jennifer A.
    CANCER DISCOVERY, 2018, 8 (10) : 1300 - 1315
  • [7] Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia
    Hansenne, Amandine
    Camboni, Alessandra
    Van den Neste, Eric
    Bailly, Sarah
    LEUKEMIA & LYMPHOMA, 2021, 62 (12) : 3051 - 3053
  • [8] Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib
    Hampel, Paul J.
    Cherng, Hua-Jay J.
    Call, Timothy G.
    Ding, Wei
    Khanlari, Mahsa
    McPhail, Ellen D.
    Miranda, Roberto N.
    Lin, Pei
    Tawbi, Hussein A.
    Ferrajoli, Alessandra
    Wierda, William G.
    Jain, Nitin
    Parikh, Sameer A.
    BLOOD ADVANCES, 2020, 4 (18) : 4508 - 4511
  • [9] A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome
    Tadmor, Tamar
    Benjamini, Ohad
    Goldschmidt, Neta
    Kreiniz, Natalia
    Bairey, Osnat
    Harel, Reut
    Inbar, Tsofia
    Wolach, Ofir
    Herishanu, Yair
    BLOOD, 2023, 142
  • [10] Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy
    Liu, Hui
    Miao, Yi
    Ferrajoli, Alessandra
    Tang, Guilin
    McDonnell, Timothy
    Medeiros, L. Jeffrey
    Hu, Shimin
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (10) : 1221 - 1223
12345